Loading
A phase 3 trial of Abemaciclib and Fulvestrant in advanced solid tumours, run by LeonaBio, now recruiting.
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation is a phase 3 interventional study registered as NCT05696626 by LeonaBio, with 600 participants planned, started 2023-10-31 and due to reach its primary completion in 2027-04. Interventions recorded: Lasofoxifene in combination with abemaciclib and Fulvestrant in combination with abemaciclib.
Shares Abemaciclib, Fulvestrant, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Abemaciclib, CDK4/6 inhibitors, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Abemaciclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Abemaciclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Fulvestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.